Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
Crystallization
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
Crystallization
Emergency use authorization Experimental Antiviral Jan/23/2023
Nirmatrelvir
Crystallization
Emergency use authorization Experimental Antiviral Jun/23/2022
Bamlanivimab
Crystallization
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
Crystallization
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
S309
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
BNT162b2
Crystallization
Approved by FDA Experimental Vaccine Jun/22/2022
Cilgavimab
Crystallization
Emergency use authorization Experimental Antiviral Jun/18/2022
Tixagevimab
Crystallization
Emergency use authorization Experimental Antiviral Jun/18/2022
Convalescent plasma
Crystallization
Emergency use authorization Experimental Antiviral May/16/2022
PF-00835231
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/26/2022
P2C-1F11
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/25/2022
S2K146
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/06/2022
mAb 222
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-55
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-29
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb 58
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-54
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb 253
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-53
Crystallization
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022